Biote Corp. Reports Solid 2024 Financial Performance

Biote Corp. ( (BTMD) ) has released its Q4 earnings. Here is a breakdown of the information Biote Corp. presented to its investors.

Biote Corp., a prominent player in the preventive healthcare sector, specializes in personalized hormone optimization and therapeutic wellness solutions. The company recently released its financial results for the fourth quarter and full year of 2024, highlighting a strengthened business through the launch of BioteRx and enhancements to its Biote Method.

In the fourth quarter of 2024, Biote reported a revenue of $49.8 million, marking a 9% increase from the previous year. Despite challenges such as transitioning to upgraded clinical decision support software, the company maintained a robust gross profit margin of 71.8%. For the full year, Biote achieved a revenue of $197.2 million, a 6.4% increase from 2023, with a net income of $0.05 million, reversing a net loss from the previous year.

Key financial metrics for the year included an adjusted EBITDA of $58.2 million and a margin of 29.5%. The company’s strategic initiatives, such as the integration of its 503B manufacturing facility and the growth of Asteria Health, contributed to improved operational efficiencies and supply chain optimization. The company ended the year with a strong cash position of $39.3 million.

Looking ahead to 2025, Biote’s management is focused on maximizing the value of its top-tier providers, expanding its practitioner network, and enhancing commercial execution. The company anticipates revenue growth driven by these initiatives, with expected increases in procedure and dietary supplement revenues. Biote remains committed to generating strong operating cash flow while investing in future growth opportunities.